NCT Number: NCT02048514
The Nellix® EndoVascular Aneurysm Sealing System for the Treatment of Infrarenal Abdominal Aortic Aneurysms
The purpose of this clinical study is to evaluate the safety and device performance of the Nellix® EndoVascular Aneurysm Sealing System (Nellix System) for the treatment of infrarenal abdominal aortic aneurysms.
Looking for future studies?
Notify MeKey information
Conditions
Age range
18 year and older
Sex eligibility
All sexes
Study type
Interventional
Phase
Not applicable
Primary location
Centro Medico de Cali, Cali, Colombia
About this study
This is a multicenter, multi-country prospective, single-arm, non-randomized clinical trial. The comparative control arm is a combination of patient data drawn from the abdominal aortic aneurysms (AAA) open surgical control arms of four commercially approved AAA devices as part of the Society of Vascular Surgeons. Patients enrolled in this study will be pre-screened and have a diagnosis of an infrarenal AAA with or without the need for treatment of iliac artery aneurysm, are candidates for endovascular repair, and meet the eligibility criteria. Patients enrolled in the study will participate in follow-up visits 31 days, 6 months and at 1 year following the index procedure. At the follow-up visits there will be a clinical assessment, blood collection, and abdominal CT imaging of the patient.
Who can participate
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
- At least 18 years of age
- Informed consent form understood and signed and patient agrees to all follow-up visits
- Is able and willing to comply with clinical follow-up requirements for one year
- Is able and willing to undergo Contrast-Enhanced Spiral CT scans
- Is a candidate for endovascular repair of an infrarenal aortic aneurysm with or without an iliac aneurysm with at least one of the following;
- aneurysm ≥ 4.5 cm in diameter, or
- aneurysm is twice the diameter of the normal infrarenal aorta, or
- aneurysm is growing at a rate of ≥ 10 % per year
- Non-aneurysmal aortic neck length ≥ 5mm below the most inferior renal artery
- Proximal aortic neck diameter between 16 and 36mm
- Aortic neck angulation to the sac ≤ 60
- Common iliac artery diameter 8 to 35mm bilaterally
- Aneurysm blood lumen diameter ≤ 60mm
- Iliac and femoral arteries suitable for endovascular access with the Nellix System
Exclusion criteria
- Life expectancy ≤ 1 year
- Dissecting, ruptured, or leaking aneurysm (blood outside the aorta), has sustained recent trauma, is symptomatic, or is non-degenerative
- Aneurysm is thoraco-abdominal, suprarenal and/or mycotic
- Thoracic aneurysm ≥ 4.5cm in diameter
- AAA requires treatment that would result in bilateral occlusion of the internal iliac arteries
- Presence of mural thrombus > 50% circumferentially in aortic neck
- Iliac aneurysm blood lumen diameter > 35mm
- Active infection, vasculitis, or systemic connective tissue disease (e.g., Rheumatoid arthritis, scleroderma, Marfan's syndrome, Ehlers-Danlos disease) at time of procedure
- History of prior treatment of abdominal aortic or iliac artery aneurysm disease
- Femoral or iliac artery occlusive disease such that device delivery is not possible
- Vascular access for delivery of device requires placement of vascular conduit or is through an established vascular graft
- Receiving dialysis
- History of hypercoagulability
- Allergy to IV contrast
- Serum creatinine level >2.0 mg/dL (or equivalent)
- Patient is pregnant or nursing
- Patient is currently enrolled in an investigational drug or device trial
Treatment and study plan
Primary outcomes
-
Safety- Number of Major Adverse Events
Time frame: 30 day
The primary safety endpoint is defined as the incidence of Major Adverse Events (MAE) through 30 days after the index procedure.
-
Device Performance
Time frame: 30 days
The primary performance endpoint is technical success defined as successful delivery and deployment of the device and freedom from open surgical conversion at 30 days.
Secondary outcomes
-
All Cause Mortality
Time frame: 12 months
Any death occurring during the study period, regardless of cause
Sponsors and collaborators
Lead sponsor
Endologix
Industry
Registry information
Important dates
- Study start
- 2008
- Primary completion
- 2017
- Study completion
- 2017
- First posted
- Jan 29, 2014
- Registry last updated
- Mar 9, 2021
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Related clinical trials
Published trials that share one or more normalized conditions with this study.
Iliac Branch Excluder ReGistry (IceBERG)
NCT02345005
Abdominal Aortic Aneurysms, Aneurysm
Brescia, Italy
View Trial DetailsEuropean (EU) Post Approval Study of the INCRAFT® AAA Stent Graft System in Subjects With Abdominal Aortic Aneurysms
NCT02477111
Abdominal Aortic Aneurysms, Aneurysm
Bordeaux, France
View Trial DetailsValidation of Fenestrations Positioning by Numerical Simulation
NCT03469245
Abdominal Aortic Aneurysms, Aneurysm
Vienna, Austria
View Trial DetailsPhysician-Sponsored IDE for Talent Endoluminal Spring Graft System in Patients With Abdominal Aortic Aneurysms (AAA)
NCT00695253
Abdominal Aortic Aneurysms, Aneurysm
Torrance, California, United States
View Trial Details